Two large, well-conducted trials of omega-3 fatty acids reached different conclusions about cardiovascular benefit — and the difference is not really a contradiction once you account for formulation and dose.
The VITAL trial tested a standard 1g/day mixed EPA/DHA fish oil capsule in a general population and found no significant reduction in major cardiovascular events or all-cause mortality. REDUCE-IT tested a high-dose (4g/day) purified EPA-only formulation in a high-risk statin-treated population and found a large, statistically robust 25% relative risk reduction in major adverse cardiovascular events.
These are frequently cited against each other as if they contradict — they largely don't. They tested different doses, different formulations (mixed EPA/DHA versus purified EPA), and different risk populations (general adults versus statin-treated patients with elevated triglycerides and existing cardiovascular disease or diabetes).
A frequently raised critique of REDUCE-IT is its placebo: mineral oil, which some analyses suggest may have modestly raised inflammatory markers and LDL cholesterol in the control arm, potentially inflating the apparent benefit of EPA. This remains debated in the cardiology literature and has not been resolved by a head-to-head replication using an inert comparator.
STRENGTH, a separate trial testing a high-dose mixed EPA/DHA formulation (rather than purified EPA) in a similar high-risk population, was stopped early for futility — it found no cardiovascular benefit and was terminated for lack of efficacy, not safety. Read alongside REDUCE-IT, this is consistent with a real hypothesis that purified EPA specifically, not omega-3s generally, may carry the cardiovascular signal — but this remains an active, unresolved question rather than a settled one.
Standard-dose mixed omega-3 supplementation has not shown a general-population mortality or cardiovascular benefit in the largest trial to date (VITAL). High-dose purified EPA showed a large effect in a specific high-risk population (REDUCE-IT), with an unresolved question about how much of that effect reflects the active drug versus the comparator. These are not interchangeable products or claims, despite frequently being marketed as such.
This information is provided for educational reference only and does not constitute medical advice or a treatment recommendation.